These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 22390762)

  • 1. Tubulins as therapeutic targets in cancer: from bench to bedside.
    Katsetos CD; Dráber P
    Curr Pharm Des; 2012; 18(19):2778-92. PubMed ID: 22390762
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel mutations involving βI-, βIIA-, or βIVB-tubulin isotypes with functional resemblance to βIII-tubulin in breast cancer.
    Wang W; Zhang H; Wang X; Patterson J; Winter P; Graham K; Ghosh S; Lee JC; Katsetos CD; Mackey JR; Tuszynski JA; Wong GK; Ludueña RF
    Protoplasma; 2017 May; 254(3):1163-1173. PubMed ID: 27943021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging microtubule targets in glioma therapy.
    Katsetos CD; Reginato MJ; Baas PW; D'Agostino L; Legido A; Tuszyn Ski JA; Dráberová E; Dráber P
    Semin Pediatr Neurol; 2015 Mar; 22(1):49-72. PubMed ID: 25976261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies.
    Dumontet C; Jordan MA; Lee FF
    Mol Cancer Ther; 2009 Jan; 8(1):17-25. PubMed ID: 19139109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of betaIII- and betaIV-tubulin isotypes in cold-adapted microtubules from Atlantic cod (Gadus morhua): antibody mapping and cDNA sequencing.
    Modig C; Olsson PE; Barasoain I; de Ines C; Andreu JM; Roach MC; Ludueña RF; Wallin M
    Cell Motil Cytoskeleton; 1999; 42(4):315-30. PubMed ID: 10223637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism of action of ixabepilone and its interactions with the βIII-tubulin isotype.
    Lopus M; Smiyun G; Miller H; Oroudjev E; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1013-24. PubMed ID: 26416565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
    Katsetos CD; Draber P; Kavallaris M
    Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
    De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of eribulin on microtubule binding and dynamic instability are strengthened in the absence of the βIII tubulin isotype.
    Wilson L; Lopus M; Miller HP; Azarenko O; Riffle S; Smith JA; Jordan MA
    Biochemistry; 2015 Oct; 54(42):6482-9. PubMed ID: 26435331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. βIII-Tubulin: biomarker of taxane resistance or drug target?
    Karki R; Mariani M; Andreoli M; He S; Scambia G; Shahabi S; Ferlini C
    Expert Opin Ther Targets; 2013 Apr; 17(4):461-72. PubMed ID: 23379899
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Emerging Role for Tubulin Isotypes in Modulating Cancer Biology and Chemotherapy Resistance.
    Parker AL; Teo WS; McCarroll JA; Kavallaris M
    Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28677634
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Microtubule Targeting Agents as Cancer Chemotherapeutics: An Overview of Molecular Hybrids as Stabilizing and Destabilizing Agents.
    Tangutur AD; Kumar D; Krishna KV; Kantevari S
    Curr Top Med Chem; 2017; 17(22):2523-2537. PubMed ID: 28056738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delineating the interaction of combretastatin A-4 with αβ tubulin isotypes present in drug resistant human lung carcinoma using a molecular modeling approach.
    Kumbhar BV; Bhandare VV; Panda D; Kunwar A
    J Biomol Struct Dyn; 2020 Feb; 38(2):426-438. PubMed ID: 30831055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tubulin: Structure, Functions and Roles in Disease.
    Binarová P; Tuszynski J
    Cells; 2019 Oct; 8(10):. PubMed ID: 31652491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence for microtubule target engagement in tumors of patients receiving ixabepilone.
    Zhuang SH; Hung YE; Hung L; Robey RW; Sackett DL; Linehan WM; Bates SE; Fojo T; Poruchynsky MS
    Clin Cancer Res; 2007 Dec; 13(24):7480-6. PubMed ID: 18094432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Taxanes with high potency inducing tubulin assembly overcome tumoural cell resistances.
    Matesanz R; Trigili C; Rodríguez-Salarichs J; Zanardi I; Pera B; Nogales A; Fang WS; Jímenez-Barbero J; Canales A; Barasoain I; Ojima I; Díaz JF
    Bioorg Med Chem; 2014 Sep; 22(18):5078-90. PubMed ID: 25047938
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TAPping into the treasures of tubulin using novel protein production methods.
    Yu N; Galjart N
    Essays Biochem; 2018 Dec; 62(6):781-792. PubMed ID: 30429282
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.